South San Francisco, CA - January 21, 2008 - Hyperion Therapeutics, Inc. today announced the appointment of Mark Spring as Senior Vice President and Chief Financial Officer.
Mr. Spring joins Hyperion from MedImmune, Inc. where he served as Vice President of Finance and Controller. In this role he was responsible for the company’s planning, accounting and financial reporting functions, and oversaw the finance teams supporting the R&D, sales and marketing, and operations functions. Previously, Mr. Spring was Vice President, Finance for Baxter International’s global renal division. Earlier in his career, he held senior finance leadership roles at Dade Behring, Caremark and PricewaterhouseCoopers. Mr. Spring holds a bachelor’s degree in business administration from Monmouth College and is a certified public accountant.
“We are very excited to have Mark join Hyperion as our CFO,” said Chris Rivera, President and CEO. “Having someone with his background, experience and industry track record is essential to our strategic growth as we seek to drive revenues from two on-market FDA-approved products and further the development of our two clinical programs.”
About Hyperion Therapeutics
Hyperion Therapeutics is a fully-integrated, privately-held specialty therapeutics company focused on becoming a global leader in hepatology and gastrointestinal (GI) therapeutic programs and products that address orphan and underserved patient populations with unmet medical needs. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: www.hyperiontx.com.
President and CEO
Hyperion Therapeutics, Inc.